Management of IgAN

CE / CME

Improving Outcomes in IgAN: Expert Guidance on Evolving Management and Treatment

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: July 01, 2024

Expiration: June 30, 2025

Pietro Canetta
Pietro Canetta, MD, MS

Activity

Progress
1 2
Course Completed

How many patients with IgA nephropathy (IgAN) do you provide care for in a typical month?

Which of the following works by inhibiting Gd-IgA1 production and possibly Hit 1 of the 4-hit hypothesis in the pathogenesis of IgAN?

A 37-year-old male patient with IgAN, hypertension, and obesity is currently receiving lisinopril 40 mg/day and dapagliflozin 10 mg/day. Blood pressure is well controlled, estimated glomerular filtration rate is 45 mL/min/1.73 m2, but urine protein has been consistently elevated. All other labs are within normal limits. Based on results of the PROTECT trial, which of the following treatment options would be the best next step to target a rapid and sustained proteinuria reduction for him?

Introduction

In this module, Pietro Canetta, MD, details the pathogenesis and multihit model of IgAN and discusses the latest in optimizing care, including recent clinical data, guidelines, and regulatory approvals. Throughout the module, gain valuable insights from a patient with lived experience through brief audio clips.

In addition, the key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.